The acquisition will strengthen Lupin’s India Formulation enterprise by including a fast-growing portfolio of nutritional vitamins, minerals, dietary supplements and neurological merchandise
Lupin introduced the completion of a portfolio of manufacturers from Anglo-French Medication & Industries Restricted (AFDIL) and its Associates.
The acquisition will strengthen Lupin’s India Formulation enterprise by including a fast-growing portfolio of nutritional vitamins, minerals, dietary supplements and neurological merchandise. The acquisition of the AFDIL manufacturers takes Lupin additional in shaping its portfolio to emerge as a number one pharmaceutical firm in India.
“With this portfolio, Lupin can have a stronger market presence, offering healthcare professionals and sufferers with a extra significant and complete product providing,” stated Nilesh Gupta, MD, Lupin.
“We’re assured in Lupin’s capability to boost the worth of our portfolio of manufacturers,” stated Abhay Kanoria, CMD, AFDIL.
Shailesh Gadre, Founder, GCV Life was the unique advisor for the transaction.